----item----
version: 1
id: {B122BC35-2C0B-42DC-8454-723F8E0D45C8}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/05/01/US quarterly results roundup
parent: {15F58FFA-40DD-4E79-AF60-F1AAEC858239}
name: US quarterly results roundup
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 241067ff-2347-4645-a83b-dd6192f8c42e

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 29

US quarterly results round-up
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1569

<p><pre>Advanced Technology Laboratories Revenues Net income (loss) ($ millions) ($ millions) 1995 1994 1995 1994 3 months 94.36 89.36 (0.27) 0.30 (ended Mar 31st, 1995; Apr 1st, 1994)</pre><p>ATL attributes increased first-quarter sales to an improved product mix and higher average prices for its new HDI 3000 fourth-generation ultrasound system. At $12.6 million, R&D was flat compared with the first quarter of 1994 and down 15% from the fourth quarter of 1994.</p><pre><strong>[C#198601285:Allergan]</strong> Revenues Net income ($ millions) ($ millions) 1995 1994 1995 1994 3 months 228.30 210.10 21.70 22.20 (ended Mar 31st)</pre><p>Allergan's ophthalmic surgical business had sales of $40.1 million in the first quarter, up 47% compared with the previous year. The company attributed this rise to acquisitions - Ioptex last year and Optical Micro Systems in January - and internal sales growth of 27%. Strong growth in international and domestic sales continued to be partially offset by pricing pressure on IOLs in the US market, the company says.</p><pre>Meridian Diagnostics Revenues Net income ($ millions) ($ millions) 1995 1994 1995 1994 3 months 6.47 5.89 0.95 0.61 6 months 11.57 9.52 1.38 0.81 (ended Mar 31st)</pre><p>At the beginning of May, chairman William Motto will take over as CEO from Jerry Ruyan. The latter will continue as secretary and a director of the company. The company received FDA approval for its Premier H pylori test in March (see Clinica No 646, p 18), and for its Premier EHEC E coli test in April (see this issue page 20).</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

US quarterly results roundup
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950501T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950501T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950501T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052396
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 29

US quarterly results round-up
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198601285
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

254216
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184148Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

241067ff-2347-4645-a83b-dd6192f8c42e
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184158Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
